Summary
Therapy with oral 5-aminosalicylic acid for inflammatory bowel disease has been reported as effective and safe. We report two cases of biochemically proven mild acute pancreatitis occurring 2 and 14 days, respectively, after oral 5-aminosalicylic acid therapy was instituted for inflammatory bowel disease. A hypersensitivity mechanism might be involved, owing to possible erratic systemic absorption of the drug. We suggest clinical and biochemical monitoring for patients undergoing oral 5-aminosalicylic acid therapy in order to confirm its possible association with acute pancreatitis and to assess the actual incidence of such an adverse reaction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J 285:1012, 1982
Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. Br Med J 287:23–24, 1982
Dew MJ, Harries AD, Evans BK, Rhodes J: Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. Lancet 2:801, 1983
Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: A randomized study. N Engl J Med 317:1625–1629, 1987
Azad-Kahn AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977
Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J: An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 14:405–408, 1982
Gionchetti P, Campieri M, Belluzzi A, Brunetti G, Tampieri M, Iannone P, Pasquali S, Brignola C, Miglioli M, Barbara L: Maintenance treatment of ulcerative colitis (UC) with oral 5-aminosalicylic acid (5-ASA) in patients unable to take sulphasalazine (SASP). Scand J Gastroenterol 24(suppl 158):135, 1989
Austin CA, Cann PA, Jones TH, Holdsworth CD: Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis. Lancet 1:917–918, 1984
Poldermans D, van Blankenstein M: Pancreatitis induced by disodium azodisalicylate. Am J Gastroenterol 83:578–580, 1988
Sachedina B, Saibil F, Cohen LB, Whittey J: Acute pancreatitis due to 5-aminosalicylate. Ann Intern Med 110:490–492, 1989
Grimaud JC, Mailot A, Bremondy A, Thervet L, Salducci J: Faut-il toujours accuser la sulfapyridine? A propos d'un cas de pancréatite aigue induite par la mésalazine. Gastroenterol Clin Biol 13:432, 1989
Deprez P, Descamps CH, Fiasse R: Pancreatitis induced by 5-aminosalicylic acid. Lancet 2:445–446, 1989
Meltzer SJ, Korelitz B: Pancreatitis and duodenopancreatic reflux in Crohn's disease: J Clin Gastroenterol 10(5):555–558, 1988
Katz S, Bank S, Greenberg RE, Lendvai S, Lesser M, Napolitano B: Hyperamylasemia in inflammatory bowel disease. J Clin Gastroenterol 10(6):627–630, 1988
Cabooter M, Elewaut A, Barbier F: Salicylate-induced pancreatitis. Gastroenterology 80:214–215, 1981
Sussman S: Severe salicylism and acute pancreatitis. Calif Med 99:29–32, 1963
Reber HA, Roberts C, Way LW: The pancreatic duct mucosal barrier. Am J Surg 137:128–134, 1979
Klotz U, Maier KE: Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig Dis Sci 32(12):46S-50S, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fiorentini, M.T., Fracchia, M., Galatola, G. et al. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Digest Dis Sci 35, 1180–1182 (1990). https://doi.org/10.1007/BF01537594
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01537594